...
首页> 外文期刊>Journal of Neuroscience Research >The Selective Noradrenergic Reuptake Inhibitor Reboxetine Restores Spatial Learning Deficits, Biochemical Changes, and Hippocampal Synaptic Plasticity in an Animal Model of Depression
【24h】

The Selective Noradrenergic Reuptake Inhibitor Reboxetine Restores Spatial Learning Deficits, Biochemical Changes, and Hippocampal Synaptic Plasticity in an Animal Model of Depression

机译:选择性的诺拉德肾上腺素能再生抑制剂Reboxetine在抑郁症的动物模型中恢复空间学习缺陷,生物化学变化和海马突触可塑性

获取原文
获取原文并翻译 | 示例
           

摘要

Depression is a major psychiatric illness that is associated with cognitive dysfunctions. The underlying mechanism of depression-associated memory impairment is unclear. Previously, we showed altered hippocampal synaptic plasticity in an animal model of depression. Although several antidepressants are beneficial in the treatment of depression, very little is known about the effects of these drugs on depression-associated learning and memory deficits. Prolonged antidepressant treatment might contribute to neuroplastic changes required for clinical outcomes. Accordingly, we evaluated the effect of chronic reboxetine (a selective noradrenergic reuptake inhibitor) treatment on depression-induced reduced hippocampal synaptic plasticity, neurotransmitter levels, and spatial learning and memory impairments. Depression was induced in male Wistar rats by the administration of clomipramine from postnatal days 8 to 21, and these rats were treated with reboxetine in adulthood. The neonatal clomipramine administration resulted in impaired hippocampal long-term potentiation (LTP), decreased hippocampal cholinergic activity and monoamine levels, and poor performance in a partially baited eight-arm radial maze task. Chronic reboxetine treatment restored the hippocampal LTP, acetylcholinesterase activity, and levels of biogenic amines and ameliorated spatial learning and memory deficits in the depressed state. Thus, restoration of hippocampal synaptic plasticity might be a cellular mechanism underlying the beneficial effect of reboxetine in depression-associated cognitive deficits. This study furthers the existing understanding of the effects of antidepressants on learning, memory, and synaptic plasticity and could ultimately assist in the development of better therapeutic strategies to treat depression and associated cognitive impairments. (c) 2014 Wiley Periodicals, Inc.
机译:抑郁症是一种与认知功能障碍有关的重大精神病疾病。抑郁相关内存障碍的潜在机制尚不清楚。此前,我们在抑郁症的动物模型中表明海马突触可塑性改变。虽然有几种抗抑郁药在治疗抑郁症的抑制作用中有益,但很少是已知这些药物对抑郁相关的学习和记忆缺陷的影响。延长的抗抑郁药治疗可能有助于临床结果所需的神经塑性变化。因此,我们评估了慢性重新抑制素(一种选择性的去甲肾上腺素能再摄取抑制剂)治疗对抑郁诱导的海马突触塑性,神经递质水平和空间学习和记忆障碍的影响。通过从产后8至21〜21所述划分的氯甲胺诱导抑郁症在雄性Wistar大鼠中诱导,并将这些大鼠用成年期的Reboxetine处理。新生儿划分的氯胺给药导致海马长期增强(LTP)受损,降低海马胆碱能活性和单胺水平,并且在部分诱导的八臂径向迷宫任务中的性能不佳。慢性重新抑制治疗恢复了海马LTP,乙酰胆碱酯酶活性和生物胺的水平,并且在凹陷状态下改善了空间学习和记忆缺陷。因此,海马突触塑性的恢复可能是雷嵌丁胺在抑郁相关的认知缺陷中的有益作用的细胞机制。本研究传统的了解抗抑郁药对学习,记忆和突触可塑性的影响,最终可能有助于开发更好的治疗策略来治疗抑郁和相关的认知障碍。 (c)2014 Wiley期刊,Inc。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号